MedTrace Logo

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

NCT00107913 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2005-06-24

No results posted yet for this study

Summary

This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).

Conditions

  • Autoimmune Thrombocytopenic Purpura

Interventions

DRUG

Doxil

Sponsors & Collaborators

  • Hematology and Oncology Specialists

    lead OTHER

Principal Investigators

  • Thomas M Cosgriff, MD · Hematology and Oncology Specialists

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Completion
2005-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00107913 on ClinicalTrials.gov